HilleVax, Inc. (NASDAQ:HLVX) CFO Sells $53,389.68 in Stock

HilleVax, Inc. (NASDAQ:HLVXGet Free Report) CFO Shane Maltbie sold 3,576 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total transaction of $53,389.68. Following the completion of the sale, the chief financial officer now owns 40,656 shares of the company’s stock, valued at approximately $606,994.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

HilleVax Stock Up 3.3 %

Shares of HilleVax stock traded up $0.49 during midday trading on Monday, reaching $15.49. 120,956 shares of the company’s stock traded hands, compared to its average volume of 125,796. The company has a market cap of $750.34 million, a price-to-earnings ratio of -5.49 and a beta of 0.52. The company’s 50 day simple moving average is $15.02 and its 200 day simple moving average is $13.75. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.58 and a current ratio of 17.58. HilleVax, Inc. has a 52 week low of $9.94 and a 52 week high of $19.09.

HilleVax (NASDAQ:HLVXGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.03. Equities analysts expect that HilleVax, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HLVX. HC Wainwright assumed coverage on shares of HilleVax in a research report on Wednesday, December 13th. They issued a “buy” rating and a $28.00 target price for the company. Guggenheim cut their price target on shares of HilleVax from $38.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Finally, Stifel Nicolaus cut their price target on shares of HilleVax from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 10th.

Get Our Latest Research Report on HLVX

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. American International Group Inc. raised its holdings in HilleVax by 21.3% in the 2nd quarter. American International Group Inc. now owns 10,216 shares of the company’s stock worth $176,000 after acquiring an additional 1,791 shares during the period. Tekla Capital Management LLC bought a new position in HilleVax in the 2nd quarter worth $464,000. Federated Hermes Inc. raised its holdings in HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after acquiring an additional 943 shares during the period. Acuta Capital Partners LLC raised its holdings in HilleVax by 328.5% in the 3rd quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock worth $3,636,000 after acquiring an additional 207,241 shares during the period. Finally, Fred Alger Management LLC raised its holdings in HilleVax by 38.6% in the 3rd quarter. Fred Alger Management LLC now owns 120,634 shares of the company’s stock worth $1,623,000 after acquiring an additional 33,591 shares during the period. Institutional investors own 89.77% of the company’s stock.

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Stories

Insider Buying and Selling by Quarter for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.